FI20075971A0 - Koostumus steriilin tulehduksen hoitoon - Google Patents

Koostumus steriilin tulehduksen hoitoon

Info

Publication number
FI20075971A0
FI20075971A0 FI20075971A FI20075971A FI20075971A0 FI 20075971 A0 FI20075971 A0 FI 20075971A0 FI 20075971 A FI20075971 A FI 20075971A FI 20075971 A FI20075971 A FI 20075971A FI 20075971 A0 FI20075971 A0 FI 20075971A0
Authority
FI
Finland
Prior art keywords
sterile
composition
treating
pharmaceutical composition
treatment
Prior art date
Application number
FI20075971A
Other languages
English (en)
Swedish (sv)
Other versions
FI20075971A (fi
FI122450B (fi
Inventor
Thomas Tallberg
Original Assignee
Helsingin Bioimmunoterapialait
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsingin Bioimmunoterapialait filed Critical Helsingin Bioimmunoterapialait
Publication of FI20075971A0 publication Critical patent/FI20075971A0/fi
Priority to FI20075971A priority Critical patent/FI122450B/fi
Priority to PL08868549T priority patent/PL2234611T3/pl
Priority to RU2010130889/15A priority patent/RU2462244C2/ru
Priority to NZ597976A priority patent/NZ597976A/xx
Priority to JP2010540153A priority patent/JP5378406B2/ja
Priority to ES08868549T priority patent/ES2381690T3/es
Priority to NZ597977A priority patent/NZ597977A/xx
Priority to AT08868549T priority patent/ATE544450T1/de
Priority to NZ586496A priority patent/NZ586496A/en
Priority to PCT/FI2008/050750 priority patent/WO2009083643A2/en
Priority to DK08868549.0T priority patent/DK2234611T3/da
Priority to BRPI0821919-2A priority patent/BRPI0821919A2/pt
Priority to KR1020107016810A priority patent/KR20100103856A/ko
Priority to EP08868549A priority patent/EP2234611B1/en
Priority to CN2008801231858A priority patent/CN101917983B/zh
Priority to US12/810,150 priority patent/US20100291235A1/en
Priority to DE08868549T priority patent/DE08868549T1/de
Priority to AU2008345508A priority patent/AU2008345508B2/en
Publication of FI20075971A publication Critical patent/FI20075971A/fi
Priority to IL206596A priority patent/IL206596A0/en
Priority to HK10110064.8A priority patent/HK1143539A1/xx
Application granted granted Critical
Publication of FI122450B publication Critical patent/FI122450B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
FI20075971A 2007-12-28 2007-12-28 Koostumus steriilin inflammaation hoitoon FI122450B (fi)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FI20075971A FI122450B (fi) 2007-12-28 2007-12-28 Koostumus steriilin inflammaation hoitoon
DK08868549.0T DK2234611T3 (da) 2007-12-28 2008-12-17 Sammensætning til behandling af steril inflammation
KR1020107016810A KR20100103856A (ko) 2007-12-28 2008-12-17 무균성 염증을 치료하기 위한 조성물
NZ597976A NZ597976A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
JP2010540153A JP5378406B2 (ja) 2007-12-28 2008-12-17 無菌性炎症の治療用組成物
ES08868549T ES2381690T3 (es) 2007-12-28 2008-12-17 Composición para tratar inflamación estéril
NZ597977A NZ597977A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
AT08868549T ATE544450T1 (de) 2007-12-28 2008-12-17 Zusammensetzung zur behandlung steriler entzündungen
NZ586496A NZ586496A (en) 2007-12-28 2008-12-17 Composition comprising neurogenic CNS lipids, arginine, lysine, leucine, chromium, tin, selenium, strontium, vanadium, wolfram and folic acid for treating sterile inflammation
PCT/FI2008/050750 WO2009083643A2 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
PL08868549T PL2234611T3 (pl) 2007-12-28 2008-12-17 Kompozycja do leczenia jałowego zapalenia
BRPI0821919-2A BRPI0821919A2 (pt) 2007-12-28 2008-12-17 Composição para tratamento de inflamação não-infecciosa
RU2010130889/15A RU2462244C2 (ru) 2007-12-28 2008-12-17 Композиция для лечения неинфекционного воспаления
EP08868549A EP2234611B1 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
CN2008801231858A CN101917983B (zh) 2007-12-28 2008-12-17 用于治疗无菌性炎症的组合物
US12/810,150 US20100291235A1 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
DE08868549T DE08868549T1 (de) 2007-12-28 2008-12-17 Zusammensetzung zur behandlung steriler entzündungen
AU2008345508A AU2008345508B2 (en) 2007-12-28 2008-12-17 Composition for treating sterile inflammation
IL206596A IL206596A0 (en) 2007-12-28 2010-06-24 Composition for treating sterile inflammation
HK10110064.8A HK1143539A1 (en) 2007-12-28 2010-10-26 Composition for treating sterile inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20075971 2007-12-28
FI20075971A FI122450B (fi) 2007-12-28 2007-12-28 Koostumus steriilin inflammaation hoitoon

Publications (3)

Publication Number Publication Date
FI20075971A0 true FI20075971A0 (fi) 2007-12-28
FI20075971A FI20075971A (fi) 2009-06-29
FI122450B FI122450B (fi) 2012-01-31

Family

ID=38951666

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20075971A FI122450B (fi) 2007-12-28 2007-12-28 Koostumus steriilin inflammaation hoitoon

Country Status (18)

Country Link
US (1) US20100291235A1 (fi)
EP (1) EP2234611B1 (fi)
JP (1) JP5378406B2 (fi)
KR (1) KR20100103856A (fi)
CN (1) CN101917983B (fi)
AT (1) ATE544450T1 (fi)
AU (1) AU2008345508B2 (fi)
BR (1) BRPI0821919A2 (fi)
DE (1) DE08868549T1 (fi)
DK (1) DK2234611T3 (fi)
ES (1) ES2381690T3 (fi)
FI (1) FI122450B (fi)
HK (1) HK1143539A1 (fi)
IL (1) IL206596A0 (fi)
NZ (3) NZ597976A (fi)
PL (1) PL2234611T3 (fi)
RU (1) RU2462244C2 (fi)
WO (1) WO2009083643A2 (fi)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012023936A1 (en) * 2010-08-18 2012-02-23 Colgate-Palmolive Company Oral care product and methods of use and manufacture thereof
FI123756B (fi) * 2010-09-21 2013-10-31 Neurofood Ab Oy Parannettu lisäravinne syövän hoitamiseksi tai ennaltaehkäisemiseksi
JP5837315B2 (ja) * 2011-03-25 2015-12-24 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
RU2156087C1 (ru) * 1999-11-25 2000-09-20 Товарищество с ограниченной ответственностью Фирма "Электронная медицина" Биологически активная добавка
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
DE60331654D1 (de) * 2003-10-17 2010-04-22 Neurofood Ab Oy Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
FI121915B (fi) * 2004-02-06 2011-06-15 Neurofood Ab Oy Koostumus psoriasiksen hoitoon
US20060062859A1 (en) * 2004-08-05 2006-03-23 Kenneth Blum Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes
US20060241040A1 (en) * 2005-04-06 2006-10-26 Alberto Visintin Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
RU2308199C2 (ru) * 2005-05-13 2007-10-20 Закрытое акционерное общество "Компания "Нутритек" (ЗАО "Компания "Нутритек") Продукт энтерального питания "нутриэн гепа"

Also Published As

Publication number Publication date
EP2234611B1 (en) 2012-02-08
WO2009083643A2 (en) 2009-07-09
RU2010130889A (ru) 2012-02-10
BRPI0821919A2 (pt) 2015-06-16
KR20100103856A (ko) 2010-09-28
AU2008345508A1 (en) 2009-07-09
HK1143539A1 (en) 2011-01-07
US20100291235A1 (en) 2010-11-18
DK2234611T3 (da) 2012-05-07
CN101917983B (zh) 2013-08-21
RU2462244C2 (ru) 2012-09-27
ES2381690T3 (es) 2012-05-30
IL206596A0 (en) 2010-12-30
NZ586496A (en) 2012-03-30
NZ597976A (en) 2012-08-31
CN101917983A (zh) 2010-12-15
ATE544450T1 (de) 2012-02-15
DE08868549T1 (de) 2011-03-17
WO2009083643A3 (en) 2009-10-29
FI20075971A (fi) 2009-06-29
PL2234611T3 (pl) 2012-07-31
AU2008345508B2 (en) 2013-11-14
JP5378406B2 (ja) 2013-12-25
FI122450B (fi) 2012-01-31
NZ597977A (en) 2012-08-31
EP2234611A2 (en) 2010-10-06
JP2011507937A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
EA201200002A1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
MY156780A (en) Substituted aromatic compounds and pharmaceutical uses thereof
WO2007006307A3 (en) Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
WO2006097337A3 (en) 11β-HYDROXYSTEROID DEHYDROGENASES
DE602007006010D1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2006003488A3 (en) Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
MX2009010407A (es) Derivados fluorados de deferiprona.
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
EA201300062A1 (ru) Фармацевтическая композиция, предназначенная для лечения заболеваний центральной и периферической нервной системы сосудистого, травматического, токсического, гипоксического и аутоиммунного генеза
EP4328218A3 (de) Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat
CL2008002384A1 (es) Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
FI20075971A0 (fi) Koostumus steriilin tulehduksen hoitoon
NO20063937L (no) Sammensetning omfattende L-serin, L-isoleucin, folsyre og sporelementer for behandling av psoriasis
RU2492163C9 (ru) Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии
PL1809270T3 (pl) Kwas 5,6,7-trihydroksyheptanowy i jego analogi do leczenia chorób oczu i chorób związanych z odpowiedziami hiperproliferacyjnymi i angiogenicznymi
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
Sahu et al. Cow urine-Therapeutic value
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
ATE489994T1 (de) Zusammensetzungen zur behandlung von luminalen entzündlichen erkrankungen
Wound Healing and Management Node Group Evidence summary: Wound management: Doxycycline for chronic wounds
ATE556079T1 (de) Verbindungen vom polyphenol-typ zur herrstellung von zusammensetzungen zur prävention oder behandlung von erkrankungen mit abnormaler zellproliferation

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: OY NEUROFOOD AB

Free format text: OY NEUROFOOD AB

FG Patent granted

Ref document number: 122450

Country of ref document: FI

MM Patent lapsed